The FDA resumed normal domestic inspections of drug facilities yesterday, citing the declining rates of COVID-19 cases across the country.

The FDA had announced on Dec. 29 that it was temporarily suspending many of its domestic and foreign inspections due to fast-spreading SARS-CoV-2 Omicron variant. The agency said it will continue to use a variety of tools to conduct both domestic and foreign mission-critical inspections, including remote assessments.

Previously planned foreign surveillance inspections that have received country clearance and are within the Center for Disease Control and Prevention’s COVID-19 travel recommendation also will proceed, the agency said.